Loading organizations...
§ Private Profile · Zürich, Zurich, Switzerland
Data and analytics platform for life sciences, connecting real-world and genomic data for precision medicine and drug development.
Based in Zurich, Switzerland, BC Platforms develops AI-enabled data networks and analytics software that connect life sciences organizations with real-world patient data for precision medicine and drug discovery. The enterprise software company employs over 100 people globally and provides researchers with secure access to clinical and genomic data covering more than 187 million patient lives across 20 countries. Operating on a business-to-business software licensing model, the firm serves top pharmaceutical companies and over 150 healthcare organizations. The organization has raised $48.4 million in total funding from lead investors including Jolt Capital, IQVIA, and Debiopharm Innovation Fund. To expand its multi-omics and medical imaging capabilities, the firm recently acquired Medexprim and established a strategic partnership with OmicsBank. BC Platforms was founded in 1997 by Timo Kanninen as a spin-off from a genomic research project at the Whitehead Institute.
BC Platforms has raised $45.0M across 3 funding rounds.
BC Platforms has raised $45.0M in total across 3 funding rounds.
BC Platforms has raised $45.0M across 3 funding rounds. Most recently, it raised $20.0M Other Equity in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 8, 2022 | $20M Venture Round | Jolt Capital | — | Announced |
| Dec 18, 2019 | $15M Series C | ROB Kotchie | Thomas Gibbs, Tesi | Announced |
| May 9, 2017 | $10M Series B | Tanja Dowe, Tesi | — | Announced |
BC Platforms has raised $45.0M in total across 3 funding rounds.
BC Platforms's investors include Jolt Capital, Rob Kotchie, Thomas Gibbs, Tesi, Tanja Dowe.